Press coverage about Innospec (NASDAQ:IOSP) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Innospec earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the specialty chemicals company an impact score of 46.0007935851604 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Innospec traded down $0.30, hitting $80.55, during trading on Thursday, according to Marketbeat.com. The company’s stock had a trading volume of 1,006 shares, compared to its average volume of 91,049. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.28 and a current ratio of 2.13. The company has a market capitalization of $1.99 billion, a PE ratio of 17.29 and a beta of 1.06. Innospec has a twelve month low of $54.10 and a twelve month high of $82.20.
Get Innospec alerts:Innospec (NASDAQ:IOSP) last issued its quarterly earnings results on Tuesday, May 8th. The specialty chemicals company reported $1.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.11. The company had revenue of $360.70 million during the quarter, compared to the consensus estimate of $308.90 million. Innospec had a return on equity of 14.91% and a net margin of 4.86%. Innospec’s revenue was up 22.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.00 EPS. equities research analysts forecast that Innospec will post 4.4 earnings per share for the current fiscal year.
Several research analysts have weighed in on IOSP shares. BidaskClub upgraded Innospec from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Johnson Rice upgraded Innospec from an “accumulate” rating to a “buy” rating in a report on Tuesday, April 24th. Zacks Investment Research upgraded Innospec from a “sell” rating to a “hold” rating in a report on Thursday, April 19th. Finally, ValuEngine downgraded Innospec from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Innospec currently has an average rating of “Buy” and an average target price of $75.00.
In other news, Director Hugh Aldous sold 1,687 shares of the company’s stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $76.72, for a total transaction of $129,426.64. Following the completion of the sale, the director now directly owns 20,705 shares in the company, valued at approximately $1,588,487.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Philip Curran sold 2,000 shares of the company’s stock in a transaction on Monday, May 14th. The stock was sold at an average price of $73.63, for a total value of $147,260.00. Following the sale, the insider now owns 4,218 shares of the company’s stock, valued at $310,571.34. The disclosure for this sale can be found here. Insiders sold a total of 15,841 shares of company stock valued at $1,209,657 over the last quarter. 2.02% of the stock is currently owned by insiders.
Innospec Company Profile
Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals for use as fuel additives, ingredients for personal care, home care, agrochemical, mining and other applications, and oilfield chemicals worldwide. It operates through four segments: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives.
No comments:
Post a Comment